COSM - Public offerings

CHICAGO, IL / ACCESSWIRE / July 25, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today provided an update on recent developments, reaffirming the management team's belief and commitment to future prospects, and highlighting CEO Greg Siokas' participation in all capital raises since inception.The Company maintains a robust balance sheet with negligible debt and a strong, diversified asset base, including tangible assets such as unencumbered freehold properties as well as machinery and equipment with a fair

CHICAGO, IL / ACCESSWIRE / July 21, 2023 / Cosmos Health Inc. (the "Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced the closing of its previously announced offering of 2,116,936 shares of the Company's common stock (or common stock equivalents in lieu thereof) in a registered direct offering and common warrants to purchase up to 1,935,484 shares of common stock in a concurrent private placement (together with the registered direct offering, the "offering"). The combined purchase price for one share of common stock (or common stock equivalent)

CHICAGO, IL / ACCESSWIRE / July 20, 2023 / Cosmos Health Inc. (the "Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that it has entered into securities purchase agreements with institutional investors for the purchase and sale of 2,116,936 shares of the Company's common stock (or common stock equivalents in lieu thereof) in a registered direct offering and common warrants to purchase up to 1,935,484 shares of common stock in a concurrent private placement (together with the registered direct offering, the "offering"). The combined purchase pri

Reduced its debt by 78% from $21.2M in 2021 to $4.6M in 2022 and expects interest expense in 2023 to be $0.6M versus $2.2M in 2022.CHICAGO, IL / ACCESSWIRE / January 17, 2023 / Cosmos Health, Inc. ("the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced an update regarding its debt balance and proforma interest expense in 2023.Cosmos Health ended 2022 with long term debt of roughly $4.6M, a reduction of $16.6M, versus the Company's 2021 debt balance of $21.2M. This is a 78% year over year debt reduction, versus the Company's previously announced guidan

MIAMI, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (NASDAQ:SMFL) ("Smart for Life" or the "Company"), a high growth global leader in the Health & Wellness sector marketing and manufacturing nutritional foods and supplements worldwide, today provided the following letter to shareholders from the Company's CEO, Darren Minton: "2022 was truly a transformative year for Smart for life and as we look toward a promising year ahead, I am proud to reflect on all that we have achieved. In the beginning of 2022, we completed our Initial Public Offering and raised gross proceeds of $14.4 million. We have now completed five major acquisitions since our formation which not only validates our

CHICAGO, IL / ACCESSWIRE / December 21, 2022 / Cosmos Health Inc. (the "Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced the closing of its previously announced registered direct offering of 2,828,320 shares of the Company's common stock and concurrent private placement of warrants to purchase 2,828,320 shares of the Company's common stock at a combined purchase price of $11.50. The warrants have an exercise price of $11.50 per share, are exercisable immediately and expire five years from the issuance date.The offering includes a $3 million par

CHICAGO, IL / ACCESSWIRE / December 19, 2022 / Cosmos Health Inc. (the "Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that it has entered into securities purchase agreements with institutional investors for the purchase and sale of 2,828,320 shares of the Company's common stock in a registered direct offering and warrants to purchase up to 2,828,320 common shares in a concurrent private placement. The combined purchase price for one share of common stock and one warrant will be $11.50. The warrants will have an exercise price of $11.50 per s

CHICAGO, IL / ACCESSWIRE / November 15, 2022 / Cosmos Holdings (d/b/a Cosmos Health, Inc.) ("the Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today provided a business update and reported financial results for the third quarter and nine months ended September 30, 2022.Third Quarter 2022 Financial HighlightsRevenues were $12.0M versus $13.6M in 3Q21. The decline in consolidated revenues was largely due to the high variation in FX differences between EUR and GBP to USD.Gross Margins were 14.8% versus 17.3% in 3Q21, due to the increase in the distribution bus

CHICAGO, IL / ACCESSWIRE / October 18, 2022 / Cosmos Holdings (d/b/a Cosmos Health, Inc.) ("Cosmos" or the "Company") (NASDAQ:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced the pricing of its "reasonable best efforts" public offering of 62,500,000 shares of common stock (or common stock equivalents), Series A Warrants to purchase 62,500,000 shares of common stock and Series B Warrant to purchase 62,500,000 shares of common stock at a combined price of $0.12 per share and warrant for aggregate gross proceeds of $7.5 million, before deducting placement agent fee

Fort Lauderdale, FL, March 01, 2022 (GLOBE NEWSWIRE) -- Exchange Listing LLC announced that its client, Cosmos Holdings, Inc. (NASDAQ:COSM) has been approved for its Nasdaq listing and commenced trading on Nasdaq Capital Market on February 28, 2022. Based in Greece, Cosmos is an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, OTC medications and medical devices. Exchange Listing advised Cosmos on all aspects of preparation and execution of the listing and financing. Simultaneous with the Nasdaq Listing, Cosmos completed the closing of a financing and private placement of Series A Convertible Preferred S

CHICAGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. ("the Company") (NASDAQ:COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and distributor of branded and generic pharmaceuticals, nutraceuticals, OTC medications and medical devices, today announced the closing of a private placement offering to certain institutional investors and an insider of the Company to purchase 6,000 shares of Series A Convertible Preferred Stock and warrants to purchase 2,000,000 shares of common stock. Each share of Series A Convertible Preferred Stock had a purchase price of $1,000.00, representing 100% of the stated value of each share of preferred stock, resu